← DiscoverAI PREDICTION · 3-MONTH VIEW
AX
AXSM
XNASAxsome Therapeutics, Inc
Mkt Cap $8.6BPHARMACEUTICAL PREPARATIONS
FUNDAMENTALS
P/S
17.90EV/EBITDA
-75.37P/B
232.23EPS (TTM)
$-3.66ROE
-345.0%ROA
-26.4%FCF
$-71.0MMKT CAP
$12.7BTECHNICAL ANALYSIS
Leaning Bearish
RSI-14
48.2
Neutral
MACD
0.000
Neutral
SMA-50
$-1.00
$-1.00
SMA-200
$-1.00
$-1.00
BOLL %B
0.30
Within bands
ATR-14
$9.64
RVOL
0.69x
Normal
MOMENTUM
-3.3%
10d -3.0% / 30d +3.2%
▲Strong edge over the market
AXSM holds a similar standing over 1 and 3 months.
WHERE IT RANKS · vs 2,129 names
20-DAY
▲Top 4%#95
60-DAY
▲Top 3%#58
TYPICAL 3-MO RANGE · vs S&P 500
+0.1%leans upper+1.1%
▸ Horizon detail
20dTop 4%
60dTop 3%
1y+analyst mean$279.33+17.2%
⚡ AI INSIGHT
Our model reads AXSM as strong both near-term and over the next few months. Analysts agree (93% Buy) — the bull case lines up.
RECENT CATALYSTS
- ANALYST_ACTIONSRBC Capital main7d
- ANALYST_ACTIONSHC Wainwright & Co. reit7d
- NEWSInitiation of FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with ADHD19d
- ANALYST_ACTIONSTD Cowen main20d
- NEWSSYMBRAVO data at AHS 68th Annual Scientific Meeting41d
REVENUE & GROWTH
$191M
Revenue
-0.0%
QoQ
+0.6%
YoY
Gross Margin
0.9%Expanding
ANALYST CONSENSUS
93% Buy
25 Buy2 Hold0 Sell
Low
$202
Mean
$279
High
$399
SHORT & FLOAT
Free Float
78.7%
Latest Headlines
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
GlobeNewswire Inc.7/14/2026
9 Health Care Stocks Whale Activity In Today’s Session
Benzinga7/8/2026
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target
Benzinga7/8/2026
RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $304
Benzinga7/7/2026
Axsome Therapeutics Doses First Patient In FOCUS-2 Phase 3 Trial Of Solriamfetol For Children With Attention Deficit Hyperactivity Disorder
Benzinga7/7/2026